KalVista Pharmaceuticals (NASDAQ:KALV) Research Coverage Started at Bank of America

Bank of America started coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a report issued on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $22.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts have also issued reports about the company. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th.

KalVista Pharmaceuticals Trading Up 3.3 %

KalVista Pharmaceuticals stock opened at $8.36 on Wednesday. The firm has a market capitalization of $413.13 million, a price-to-earnings ratio of -2.30 and a beta of 0.85. The firm’s fifty day moving average price is $10.44 and its two-hundred day moving average price is $11.66. KalVista Pharmaceuticals has a 1-year low of $7.97 and a 1-year high of $16.88.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now directly owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at $2,468,697.48. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,291 shares of company stock worth $304,086 in the last 90 days. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Barclays PLC lifted its stake in KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 54,257 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of KalVista Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock valued at $9,624,000 after buying an additional 24,713 shares during the last quarter. Zimmer Partners LP grew its stake in shares of KalVista Pharmaceuticals by 52.6% during the 3rd quarter. Zimmer Partners LP now owns 95,704 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after acquiring an additional 33,000 shares during the period. Wellington Management Group LLP increased its holdings in KalVista Pharmaceuticals by 40.3% in the 3rd quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company’s stock worth $1,366,000 after acquiring an additional 33,900 shares during the last quarter. Finally, State Street Corp raised its stake in KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).